Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Salt Lake City, UT
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  9/17/2014
Woodland International
mi
from
Little Rock, AR
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 9/17/2014
Woodland International
mi
from
Little Rock, AR
Click here to add this to my saved trials
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  9/17/2014
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 9/17/2014
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  9/17/2014
Neuropsychiatric Research Center for Orange County
mi
from
Orange, CA
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 9/17/2014
Neuropsychiatric Research Center for Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  9/17/2014
Comprehensive Clinical Development
mi
from
Washington,
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 9/17/2014
Comprehensive Clinical Development
mi
from
Washington,
Click here to add this to my saved trials
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  9/17/2014
Compass Research
mi
from
Leesburg, FL
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 9/17/2014
Compass Research
mi
from
Leesburg, FL
Click here to add this to my saved trials
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  9/17/2014
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 9/17/2014
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  9/17/2014
CBH Health LLC
mi
from
Rockville, MD
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 9/17/2014
CBH Health LLC
mi
from
Rockville, MD
Click here to add this to my saved trials
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  9/17/2014
CRI Lifetree
mi
from
Marlton, NJ
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 9/17/2014
CRI Lifetree
mi
from
Marlton, NJ
Click here to add this to my saved trials
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  9/17/2014
CRI Lifetree
mi
from
Philadelphia, PA
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 9/17/2014
CRI Lifetree
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  9/17/2014
Community Clinical Research
mi
from
Austin, TX
Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 9/17/2014
Community Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
Contingency Management of Alcohol Abuse in the Severely Mentally ILL
Novel EtG-Based Contingency Management for Alcohol in the Severely Mentally Ill
Status: Enrolling
Updated:  12/1/2014
Harborview Medical Center
mi
from
Seattle, WA
Contingency Management of Alcohol Abuse in the Severely Mentally ILL
Novel EtG-Based Contingency Management for Alcohol in the Severely Mentally Ill
Status: Enrolling
Updated: 12/1/2014
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations
Bilateral rTMS Clinical Trial for Persistent Auditory Hallucinations
Status: Enrolling
Updated:  2/8/2015
Department of Psychiatry, Yale School of Medicine
mi
from
New Haven, CT
Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations
Bilateral rTMS Clinical Trial for Persistent Auditory Hallucinations
Status: Enrolling
Updated: 2/8/2015
Department of Psychiatry, Yale School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Patients (MK-8189-003)
A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8189 in Healthy Volunteers and in Schizophrenia Patients
Status: Enrolling
Updated:  4/1/2015
Clinical Research Facility
mi
from
Glendale, CA
MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Patients (MK-8189-003)
A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8189 in Healthy Volunteers and in Schizophrenia Patients
Status: Enrolling
Updated: 4/1/2015
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
A Randomized, Double-blind, Placebo Controlled, Sponsor Open, Parallel Group Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of Multiple Ascending Doses Of Pf-04958242 In Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  4/1/2015
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
A Randomized, Double-blind, Placebo Controlled, Sponsor Open, Parallel Group Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of Multiple Ascending Doses Of Pf-04958242 In Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 4/1/2015
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia
Status: Enrolling
Updated:  4/13/2015
Veteran's Administration of Greater Los Angeles
mi
from
Los Angeles, CA
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia
Status: Enrolling
Updated: 4/13/2015
Veteran's Administration of Greater Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia
Status: Enrolling
Updated:  4/13/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia
Status: Enrolling
Updated: 4/13/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia
Status: Enrolling
Updated:  4/13/2015
Maryland Psychiatric Research Center
mi
from
Catonsville, MD
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia
Status: Enrolling
Updated: 4/13/2015
Maryland Psychiatric Research Center
mi
from
Catonsville, MD
Click here to add this to my saved trials
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia
Status: Enrolling
Updated:  4/13/2015
Massachusetts General Hospital
mi
from
Boston, MA
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia
Status: Enrolling
Updated: 4/13/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia
Status: Enrolling
Updated:  4/13/2015
Research Foundation for Mental Hygiene, Inc.
mi
from
New York, NY
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia
Status: Enrolling
Updated: 4/13/2015
Research Foundation for Mental Hygiene, Inc.
mi
from
New York, NY
Click here to add this to my saved trials
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia
Status: Enrolling
Updated:  4/13/2015
Duke University School of Medicine
mi
from
Durham, NC
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia
Status: Enrolling
Updated: 4/13/2015
Duke University School of Medicine
mi
from
Durham, NC
Click here to add this to my saved trials
A Self-Management Program for Adults With Both Schizophrenia and a Co-occurring Medical Condition
Optimizing Chronic Illness Self-Management for Individuals With Schizophrenia
Status: Enrolling
Updated:  5/7/2015
Fayette Street Clinics
mi
from
Baltimore, MD
A Self-Management Program for Adults With Both Schizophrenia and a Co-occurring Medical Condition
Optimizing Chronic Illness Self-Management for Individuals With Schizophrenia
Status: Enrolling
Updated: 5/7/2015
Fayette Street Clinics
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effects of Eszopiclone on Sleep and Memory in Schizophrenia
Sleep-dependent Memory Processing in Schizophrenia
Status: Enrolling
Updated:  6/1/2015
Massachusetts General Hospital
mi
from
Boston, MA
Effects of Eszopiclone on Sleep and Memory in Schizophrenia
Sleep-dependent Memory Processing in Schizophrenia
Status: Enrolling
Updated: 6/1/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
Status: Enrolling
Updated:  6/22/2015
Connecticut Mental Health Center
mi
from
New Haven, CT
Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
Status: Enrolling
Updated: 6/22/2015
Connecticut Mental Health Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Charleston, SC
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Little Rock, AR
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Glendale, CA
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Long Beach, CA
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Oakland, CA
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Oakland, CA
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Oceanside, CA
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Orange, CA
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
San Diego, CA
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
New Britain, CT
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
New Britain, CT
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Bradenton, FL
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Kissimmee, FL
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Kissimmee, FL
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Tampa, FL
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Wichita, KA
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
East Lansing, MI
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
East Lansing, MI
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
St. Louis, MO
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Jamaica, NY
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Jamaica, NY
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Durham, NC
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Canton, OH
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Memphis, TN
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Austin, TX
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
mi
from
Bothell, WA
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
mi
from
Bothell, WA
Click here to add this to my saved trials
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated:  7/1/2015
mi
from
Buenos Aires,
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Status: Enrolling
Updated: 7/1/2015
mi
from
Buenos Aires,
Click here to add this to my saved trials
Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
An Exploratory Study to Assess the Effects of Fanapt® on Social Cognitive Performance
Status: Enrolling
Updated:  7/6/2015
Northwestern University
mi
from
Chicago, IL
Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
An Exploratory Study to Assess the Effects of Fanapt® on Social Cognitive Performance
Status: Enrolling
Updated: 7/6/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials